QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dmd.105.006569v1 34/5/734    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhang, J. G. Articles by Wong, J. Search for Related Content PubMed PubMed Citation Articles by Zhang, J. G. Articles by Wong, J.

SHORT COMMUNICATION

HUMAN CYTOCHROME P450 INDUCTION AND INHIBITION POTENTIAL OF CLEVIDIPINE AND ITS PRIMARY METABOLITE H152/81

BD Biosciences Discovery Labware, Woburn, Massachusetts (J.G.Z., S.S.D., T.H., J.J., C.C., A.P.B., R.J.C., C.L.C., D.M.S.); and the Medicines Company, Parsippany, New Jersey (J.W.)

Clevidipine is a short-acting dihydropyridine calcium channel antagonist under development for treatment of perioperative hypertension. Patients treated with clevidipine are likely to be comedicated. Therefore, the potential for clevidipine and its major metabolite H152/81 to elicit drug interactions by induction or inhibition of cytochrome P450 was investigated. Induction of CYP1A2, CYP2C9, and CYP3A4 was examined in primary human hepatocytes treated with clevidipine at 1, 10, and 100 µM. Clevidipine was found to be an inducer of CYP3A4, but not of CYP1A2 or CYP2C9, at the 10 µM and 100 µM concentrations of clevidipine tested. Induction response for CYP3A4 to 100 µM clevidipine was approximately 20% of that of the positive control inducer rifampicin. The response of H152/81 was similar. Using cDNA-expressed enzymes, clevidipine inhibited CYP2C9, CYP2C19, and CYP3A4 activities with IC₅₀ values below 10 µM, whereas CYP1A2, CYP2D6, and CYP2E1 activities were not substantially inhibited (IC₅₀ values >70 µM). The K_i values for CYP2C9 and CYP2C19 were 1.7 and 3.3 µM, respectively, and those for CYP3A4 were 8.3 and 2.9 µM, using two substrates, testosterone and midazolam, respectively. These values are at least 10 times higher than the highest clevidipine concentration typically seen in the clinic. Little or no inhibition by H152/81 was found for the enzyme activities mentioned above (IC₅₀ values 69 µM). The present study demonstrates that it is highly unlikely for clevidipine or its major metabolite to cause cytochrome P450-related drug interactions when used in the dose range required to manage hypertension in humans.

This article has been cited by other articles:

				D. F. McGinnity, G. Zhang, J. R. Kenny, G. A. Hamilton, S. Otmani, K. R. Stams, S. Haney, P. Brassil, D. M. Stresser, and R. J. Riley Evaluation of Multiple in Vitro Systems for Assessment of CYP3A4 Induction in Drug Discovery: Human Hepatocytes, Pregnane X Receptor Reporter Gene, and Fa2N-4 and HepaRG Cells Drug Metab. Dispos., June 1, 2009; 37(6): 1259 - 1268. [Abstract] [Full Text] [PDF]

				J. H. Levy, M. Y. Mancao, R. Gitter, D. J. Kereiakes, A. M. Grigore, S. Aronson, and M. F. Newman Clevidipine Effectively and Rapidly Controls Blood Pressure Preoperatively in Cardiac Surgery Patients: The Results of the Randomized, Placebo-Controlled Efficacy Study of Clevidipine Assessing Its Preoperative Antihypertensive Effect in Cardiac Surgery-1 Anesth. Analg., October 1, 2007; 105(4): 918 - 925. [Abstract] [Full Text] [PDF]